Past Grand Rounds Webinar Library
SAINT: Past, Present, and Future
Don't miss out on the Q&A portion of the webinar!
At the end of this presentation, participants will be able to:
(1) Briefly review the parameters of Stanford Accelerated Intelligent Neuromodulation Therapy (SAINT) and their rationale
(2) Discuss the results of a recent, double-blind, randomized, sham-controlled study of SAINT for treatment resistant depression (TRD)
(3) Review basics of human neuroimaging
(4) Discuss application of a novel spatio-temporal biomarker, derived using human neuroimaging, in application of SAINT
Format: On-Demand
Cost: NOW FREE
Previous Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKERS:
Nolan Williams, MD
Dr. Williams is an Assistant Professor within the Department of Psychiatry and Behavioral Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in clinical neuroscience and is triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry. In addition, he has specific training and clinical expertise in the development of brain stimulation methodologies under Mark George, MD.
Anish Mitra, MD, PhD
Dr. Mitra received his B.S. in Mathematics at Stanford prior to completing his MD/PhD at Washington University in Saint Louis. In the course of his graduate work with Marcus Raichle, Anish studied systems level spontaneous activity using human fMRI and widefield calcium imaging and electrophysiology in mice. As a postdoc, Anish is applying the Deisseroth Lab's imaging and brain stimulation techniques to investigate the mechanisms underlying organized patterns in brain-wide activity.
Ian Kratter, MD, PhD
Dr. Kratter is an adult psychiatrist and fellowship-trained neuropsychiatrist and clinical assistant professor in the Department of Psychiatry & Behavioral Sciences at Stanford University School of Medicine. He is also director of Invasive Technologies in the Stanford Brain Stimulation Laboratory. His clinical interests include the psychiatric and cognitive aspects of movement disorders like Parkinson's and Tourette's as well as depression, obsessive-compulsive disorder, and non-invasive and invasive neuromodulation for neuropsychiatric illness.
<br /> An Introduction to Transcranial Magnetic Stimulation: Beyond Depression Part 2<br />
The purpose of this Grand Rounds is to provide an introduction on TMS to interested members. This talk has been designed by the resident education taskforce for psychiatry residents to provide an overview of transcranial magnetic stimulation for depression. A copy of the slide deck will also be available online to members who view this presentation and may be used by members as a presentation template for the education of referring providers or other interested healthcare professions who have limited knowledge of TMS.
Don't miss out on our Q&A portion of the webinar!
At the end of this presentation participants will be able to:
- Know FDA cleared psychiatric indications for TMS
- Understand the basic neurobiology of OCD and addictions as related to the potential mechanism of TMS
- Review the data supporting the use of TMS for OCD and smoking cessation
- Identify the potential risks of TMS
- Understand patient appropriateness for TMS based on demographics, diagnosis, and treatment history
Format: On-Demand
Cost: FREE TO EVERYONE
CME IS NOT AVAILABLE FOR THIS GRAND ROUNDS WEBINAR
SPEAKER:
Suzanne Kerns, MD
Dr. Kerns completed her undergraduate studies at the University of North Carolina in Chapel Hill. She attended medical school at the University of Sydney in Australia, followed by a psychiatry residency at Duke University Medical Center. Dr. Kerns subsequently completed a year-long Fellowship in Brain Stimulation at the Medical University of South Carolina (MUSC) under the guidance of Dr. Mark George, a founding father of TMS. After several years of private practice at Seattle Neuropsychiatric Treatment Center with a faculty appointment at the University of Washington, she returned to MUSC, where she is now an Assistant Professor of Psychiatry on the Brain Stimulation Service. Dr. Kerns is a past member of the Board of Directors of the Clinical TMS Society, past Member-at-Large on the CTMSS Executive Committee, past Co-Chair of the CTMSS Education Committee, and she continues to proudly serve as a member of the Education Committee and Resident Education Task Force for the Clinical TMS Society.
An Introduction to Transcranial Magnetic Stimulation Part 1: TMS in Depression
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: An Introduction to Transcranial Magnetic Stimulation: TMS in Depression Part 1
The purpose of this Grand Rounds is to provide an introduction on TMS to interested members. This talk has been designed by the resident education taskforce for psychiatry residents to provide an overview of transcranial magnetic stimulation for depression. A copy of the slide deck will also be available online to members who view this presentation and may be used by members as a presentation template for the education of referring providers or other interested healthcare professions who have limited knowledge of TMS.
Don't miss out on our Q&A portion of the webinar!
At the end of this presentation participants will be able to:
- Understand the evidence for transcranial magnetic stimulation (TMS) as a treatment for depression
- Describe where TMS falls in a major depressive disorder (MDD) treatment algorithm
- Know the history of TMS
- Understand potential mechanisms of actions of TMS
- Know the efficacy rate of TMS for MDD from scientific literature
Format: On-Demand
Cost: FREE TO EVERYONE
CME IS NOT AVAILABLE FOR THIS GRAND ROUNDS WEBINAR
SPEAKER:
Kristin Raj, MD
Dr. Raj specializes in the treatment of mood disorders with expertise in neuromodulation and in the psychopharmacological management of the bipolar disorder. She is Chief of Interventional Psychiatry and Chief of the Bipolar Clinic at Stanford University. She is the director of education for interventional psychiatry where she manages resident and fellow education in brain stimulation and the development of didactics. She is also director of the neuroscience curriculum for the psychiatry residency where she has worked to create and assess a new series of interactive lectures. She trained in biomedical engineering in undergraduate at Case Western Reserve University and completed her medical degree and psychiatry residency at Stanford University. She currently serves on the Board of Directors and the Education Committee of the Clinical TMS Society.
Unidirectional Versus Rotational TMS: Which Neurons is TMS Coil Stimulating?
Don't miss out on our Q&A portion of the webinar!
At the end of this presentation participants will be able to:
- Identify how neuronal populations are stimulated with unidirectional TMS
- Identify how to stimulate more neurons with rotational field TMS
- Discuss how to answer unanswered questions with rotational field TMS
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKER:
Aron Tendler, MD
Dr. Tendler graduated in 2002 from State University of New York Downstate Medical School in Brooklyn with a distinction in research. From 2002-2004, he trained at Tulane University in Internal Medicine and Psychiatry followed by two years at the University of Chicago in General Psychiatry, where he was the chief resident of the consultation-liaison service and course director for psychosomatic medicine. Dr. Tendler is Board Certified in General Psychiatry, Sleep Medicine, Behavioral Sleep Medicine and Obesity Medicine. In 2006, Dr. Tendler established Advanced Mental Health Care Inc. in Palm Beach County, Florida. Dr. Tendler began using TMS clinically in 2009 for a variety of psychiatric and neurological conditions. Currently, he sees patients thirty hours a week, does clinical research in neurostimulation and is the chief medical officer for BrainsWay.
Perceived Barriers to Using rTMS for depression: A National Survey of Psychiatrists, Patients, Caregivers, and the General Public
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Perceived Barriers to Using rTMS for depression: A National Survey of Psychiatrists, Patients, Caregivers, and the General Public.
Don't miss out on our Q&A portion of the webinar!
At the end of this presentation participants will be able to:
-
Recognize differences in perceived barriers to using rTMS by different stakeholder groups
-
Describe key perceived barriers to using rTMS for depression
-
Understand how patient and clinician sociodemographic characteristics shape perceived barriers to TMS
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKERS:
Laura Cabrera, PhD
Dr. Cabrera is the Dorothy Foehr Huck and J. Lloyd Huck Chair in Neuroethics. She is an Associate Professor of Engineering Science and Mechanics, and Philosophy at Penn State University. She is a Research Associate at the Rock Ethics Institute, and affiliated with the Center for Neural Engineering. She is also Faculty Affiliate at Neuroethics Canada, University of British Columbia. She received a BEng in Electrical and Communication Engineering from the Instituto Tecnológico de Estudios Superiores de Monterrey (ITESM) in Mexico City, an MA in Applied Ethics from Linköping University in Sweden, and a PhD in Applied Ethics from Charles Sturt University in Australia.
Dr. Cabrera's interests focus on the ethical and societal implications of neurotechnologies used for health and medicine, as well as for non-medical purposes. She has been working on projects at the interface of normative, conceptual and empirical approaches, exploring attitudes and ethical concerns of professionals, patients and members of the public toward brain interventions. Her work has also focused on the ethical and social implications of environmental changes for brain and mental health. Her current work focuses on the responsible use of psychiatric electroceutical interventions, and the timing of deep brain stimulation for Parkinson’s Disease.
Dr. Cabrera is an honorific member of the Mexican Neuroethics Society, chair of the IEEE Brain Neuroethics Subcommittee, and member of the International Neuroethics Society (INS) Board of Directors. Her career goal is to pursue interdisciplinary neuroethics scholarship, provide active leadership, and train and mentor future leaders in the field.
Lessons from the Birthplace of TMS: TMS in the UK
Learning Objectives:
- History of development of the first TMS device
- Understanding of how mental health services are provisioned in the National Health Service (NHS) in the UK
- Understanding of how TMS is provisioned in the UK and differences between the NHS and the private sector
- Understanding of the timeline of the development of TMS from early experiments to the realization of a practical clinical tool.
Date of Release: Friday, February 4, 2022
Date of Expiration: February 3, 2024
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKERS:
Professor Anthony T Barker PhD, FIET, FIPEM
Dr. Barker recently retired from the U.K. National Health Service in 2015 after 38 years in the Department of Medical Physics and Clinical Engineering of Sheffield Teaching Hospitals NHS Foundation Trust. An engineer by training, Tony’s PhD was on the study of the distribution of peripheral nerve conduction velocities in man. During this period he started to investigate nerve stimulation using magnetically induced currents. He continued this work after his PhD and led the group which invented the technique of Transcranial Magnetic Stimulation (TMS), now widely used throughout the world for basic research, diagnosis and therapy.
Tony has an active interest in the public understanding of science and has given many named and public lectures including the Faraday lecture series, the Silvanus P Thomson series and a Royal Institution Discourse. He is an honorary Professor Associate of the University of Sheffield, a Fellow of the Institution of Engineering and Technology and of the Institute of Physics and Engineering in Medicine. He received the inaugural International Brain Stimulation Award in 2017 for the development of TMS.
Mohamed Abdelghani MBBCh, MSc, FRCPsych
Dr. Abdelghani is one of the pioneers of introducing TMS in UK clinical practice. In 2016 he founded the first clinical TMS in the NHS in London and South England at Camden and Islington NHS Foundation Trust and he continues to lead this service until the present time. He has been formally trained in TMS at two of the top TMS centres in the world; Harvard University in USA and Medical University of South Carolina (MUSC) at the hands of Prof Mark George who was the first psychiatrist to use TMS to treat depression in the early 90s.
In May 2018 he was awarded the Clinical TMS Society President’s award for his dedication, collaboration, efforts and leadership to advance the ideals of the Society. At the present time Dr Abdelghani is the chair of the Outreach Committee in the society in addition to being a member of the Educational Committee. He gives lectures and hands-on-training both nationally and internationally on the topic of TMS and neuromodulation. He is a faculty member of the PULSES TMS training course that is delivered by the Clinical TMS Society in different countries.
Leon Rozewicz MD, MBBS, FRCPsych, MRCGP, MRCPsych
Dr Rozewicz teaches medical students from University College London and has specialist expertise in using biological approaches to treat psychiatric disorders. He uses genetic testing to find the most suitable medications for each individual. Dr Rozewicz also uses repetitive transcranial magnetic stimulation (rTMS) to treat depression.
Dr Rozewicz has been a consultant psychiatrist since 1995, and has worked in the NHS for 21 years. He has been a lecturer and an honorary senior lecturer in psychiatry at St George’s Hospital Medical School in London. Prior to training in psychiatry Dr Rozewicz completed training in general practice.
Neuromodulation for ADHD
Learning Objectives:
- Review of ADHD
- To understand the condition
- To explore the current pharmacologic and psychotherapeutic approaches
- Neuromodulation for ADHD: in the pipeline and FDA-cleared
- tDCS
- TMS
- eTNS
- Q & A
Date of Release: Friday, January 7, 2022
Date of Expiration: January 6, 2024
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKER:
Ian Cook, MD, DFAPA
Dr. Cook is a Director of the Los Angeles TMS Institute, Inc., and Professor Emeritus of Psychiatry and Biobehavioral Sciences in UCLA’s David Geffen School of Medicine, where he previously held the Miller Family Endowed Chair in Depression Research, was Director of the UCLA Depression Research & Clinic Program, and was the Founding Director of the UCLA TMS Service. Dr. Cook earned his bachelors degree with high honors from Princeton University and his medical degree from the Yale University School of Medicine. He completed his psychiatry residency training at UCLA's Neuropsychiatric Institute, where he also was an NIMH-funded research fellow, before joining the faculty. Dr. Cook served on the Executive Committee on Practice Guidelines of the American Psychiatric Association and guided the electronic dissemination of their evidence-based guidelines in psychiatry. A board-certified Psychiatrist, he has also served as an examiner for the American Board of Psychiatry and Neurology. His biography is profiled in Who's Who in America, Who's Who in the World, and Best Doctors. He is the author of numerous publications on brain function in mental illness and in aging and holds several dozen patents on biomedical devices and methods.
Connectome Based TMS
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Connectome Based TMS
Learning Objectives:
- To understand how connectomics changes the way we understand the brain;
- To explore how personalized connectomic maps can augment our understanding of mood disorders and neurological disease;
- To explore how TMS can be augmented with the application of personalized brain targets based on connectomic analysis.
Date of Release: Friday, November 5, 2021
Date of Expiration: November 4, 2023
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKER:
Christos Profyris, MA(Cantab), BM BCh(Oxon), MRCS (Eng), FC Neurosurg (SA), MMed Neurosurg (Wits)
Dr Christos Profyris completed his pre-clinical medical studies at the University of Cambridge with a Double First Class and went onto finish his medical degree with Distinction at the University of Oxford. He completed his Neurosurgical training at the University of the Witwatersrand and achieved his Neurosurgery Fellowship qualification from the College of Medicine of South Africa.
Dr Profyris completed the Charles Teo Minimally Invasive Neurosurgery Fellowship under Professor Charles Teo at the Centre for Minimally Invasive Neurosurgery in Sydney Australia. During this time, he also undertook advanced training in brain mapping techniques, under Professor Mike Sughrue.
Dr Profyris is a super-specialist in brain tumour and vascular neurosurgery. Dr Profyris has a special interest in the application of keyhole and endoscopic techniques to vascular, skull base, pituitary and neuro-oncological procedures. He is head of Department at the Neurosurgery Unit at Helen Joseph Hospital in Johannesburg under the University of the Witswatersrand and also works at Netcare Milpark and Linksfield Hospital. Dr Profyris is founder of the Connectomix TMS Clinics in South Africa.
Localization, Connectivity and Mechanisms: A Neurologist's Perspective
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: TMS – Localization, Connectivity and Mechanisms: A Neurologist's Perspective
Learning Objectives:
- To understand the historic and neurological approach to brain disorders;
- To be aware of brain connectivity theories in neuropsychiatric disorders;
- To understand potential mechanisms of action of transcranial magnetic stimulation.
Date of Release: October 8, 2021
Date of Expiration: October 7, 2023
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKER:
Brian Smith, MD
Dr. Smith is a neurologist and sleep physician with board certifications in neurology, sleep medicine, and vascular neurology (stroke). He received his medical degree from Albany Medical College. He completed his medical internship at Roger Williams Medical Center in Providence, RI and his neurology training at Dartmouth Medical Center in Lebanon, NH.
He has practiced neurology and sleep medicine in academic and private practice settings and been involved in teaching and educational activities throughout his career. He has published articles and textbook chapters on topics in neurology. Four years ago he became one of the founding partners of Achieve TMS East in Massachusetts and continues to serve as the Chief Medical Officer for Achieve TMS East & Central. He is actively involved in the Clinical TMS Society and serves on the board of directors in addition to the education and membership committees.
Dual Targeting in OCD Neuromodulation: Lessons from the UCL OCD DBS Trial & Next-Generation Brain Stimulation for Obsessive-Compulsive Disorder
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Dual Targeting in OCD Neuromodulation: Lessons from the UCL OCD DBS Trial & Next-Generation Brain Stimulation for Obsessive-Compulsive Disorder
Part 1: Dual Targeting in OCD Neuromodulation: Lessons from the UCL OCD DBS Trial Presented by Himanshu Tyagi, MRCPsych, PhD
Learning Objectives:
- Understand the evolution of OCD DBS Targeting;
- Understand the core functional circuits involved in OCD;
- Clinical lessons learnt from OCD DBS Dual Targeting;
- Impact on disability and the burden of normality after the successful treatment of OCD.
Part 2: Next-Generation Brain Stimulation for Obsessive-Compulsive Disorder Presented by Alik Widge, MD, PhD
Learning Objectives:
- Describe the clinical evidence for invasive neurostimulation in psychiatry;
- Identify challenges unique to the design of clinical trials in brain stimulation;
- Describe the application of biomarker-based therapies to improve clinical neurostimulation outcomes.
Date of Release: July 9, 2021
Date of Expiration: July 8, 2023
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKERS:
Himanshu Tyagi, MRCPsych, PhD
Dr Himanshu Tyagi, MRCPsych, PhD is a medical psychotherapist and clinical academic neuropsychiatrist in the field of obsessive-compulsive and related disorders. He coordinated the first UK trial investigating Deep Brain Stimulation (DBS) in severe and treatment refractory obsessive-compulsive disorder (OCD) between 2012-2016 at UCL Queen Square Institute of Neurology. He holds a CCT in Psychotherapy (CBT), a PhD in neuroscience from UCL and was the recipient of Higher Psychiatric Trainee of the Year award from the Royal College of Psychiatrists, UK in 2012 and British Neuropsychiatric Association’s Alwyn Lishman prize in 2017. He is also a co-founder and vice chair of the Royal College of Psychiatrists network for Obsessive-Compulsive and Related Disorders (OCARD). At present he runs a specialist national clinic for OCD comorbid with Tourette syndrome at the National Hospital for Neurology and Neurosurgery, Queen Square and leads one of two specialist inpatient OCD services in England which is based in North London. He is also a co-investigator on the upcoming Op-TICS trial, looking at deep brain stimulation in patients with severe Tourette Syndrome. He routinely tweets about the latest OCD research and clinical practice tips at @himanshutyagi
Alik Widge, MD, PhD
Alik Widge, MD, PhD is a brain stimulation psychiatrist and biomedical engineer. He is an Assistant Professor of Psychiatry at the University of Minnesota, where he directs the Translational NeuroEngineering Lab. Dr. Widge completed his MD at the University of Pittsburgh, his PhD in Robotics at Carnegie Mellon University, psychiatry residency at the University of Washington, and fellowships at Massachusetts General Hospital and the Massachusetts Institute of Technology. His research focuses on brain stimulation for severe and treatment-resistant mental illness, with particular emphasis on deep brain stimulation and related implantable technologies. Dr. Widge's recent work has demonstrated new algorithms for closed-loop brain stimulation and stimulation methods for modifying connectivity in the distributed circuits of mental illness. His laboratory studies rodent models for prototyping these new technologies and human patients to identify biomarkers and targets for future intervention. He also co-leads programs to design new neurostimulation technologies in the central and peripheral nervous systems, to evaluate technologies for safety and efficacy in humans, and to improve the quality of clinical biomarker research nationwide.
Stanford Accelerated Intelligent Neuromodulation Therapy Update
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Stanford Accelerated Intelligent Neuromodulation Therapy
Learning Objectives:
- Understand the background for neuromodulation treatments for depression.
- Understand the recent findings specifically in theta burst TMS.
- Understand how a novel rapid-acting brain stimulation therapy was carried out.
Date of Release: May 7, 2021
Date of Expiration: May 6, 2023
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
Non-Member Access Instructions
SPEAKER: Nolan Williams, MD
Dr. Williams is an Assistant Professor within the Department of Psychiatry and Behavioral Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in clinical neuroscience and is triple board-certified in general neurology, general psychiatry, as well as behavioral neurology and neuropsychiatry. In addition, he has specific training and clinical expertise in the development of brain stimulation methodologies under Mark George, MD. Themes of his work include (a) examining the use of spaced learning theory in the application of neurostimulation techniques, (b) development and mechanistic understanding of rapid-acting antidepressants, and (c) identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. He has published papers in high impact peer-reviewed journals including Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. Results from his studies have gained widespread attention in journals such as Science and New England Journal of Medicine Journal Watch as well as in the popular press and have been featured in various news sources including Time, Smithsonian, and Newsweek. Dr. Williams received two NARSAD Young Investigator Awards in 2016 and 2018 along with the 2019 Gerald R. Klerman Award. Dr. Williams received the National Institute of Mental Health Biobehavioral Research Award for Innovative New Scientists in 2020.
Maintenance TMS Therapy: What is the Evidence? And Why isn’t it Covered?
Maintenance TMS Therapy: What is the Evidence? And Why isn’t it Covered?
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Maintenance TMS Therapy: What is the Evidence? And Why isn’t it Covered?
Learning Objectives:
- Review the published evidence base supporting TMS maintenance treatments after a successful acute course for depression;
- Identify the areas of gap in the evidence base and their implications;
- Consider the rationale behind several different approaches to maintenance care with TMS.
Date of Release: April 9, 2021
Date of Expiration: April 8, 2023
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
Non-Member Access Instructions
SPEAKER: Linda Carpenter, MD
Linda L. Carpenter, MD is a Professor of Psychiatry in the Alpert Medical School of Brown University and Director of the Butler Hospital TMS Clinic and Neuromodulation Research Facility. She completed her undergraduate degree at the University of Michigan and medical school at the University of Pennsylvania. She did an internship in internal medicine, psychiatry residency, and research fellowship at Yale, then joined the faculty at Brown in 1997. She has continued her path since then as a physician-researcher investigating the neurobiology of, and new treatments for, major depression and other mood and anxiety disorders. Dr. Carpenter has also conducted a number of randomized clinical trials sponsored by industry and NIH, investigating investigational drugs and devices for treating depression, including esketamine, Vagus Nerve Stimulation (VNS), Deep Brain Stimulation (DBS), Transcranial Magnetic Stimulation (TMS) and transcranial Direct Current Stimulation (tDCS). She was engaged in TMS research prior to the first FDA clearance in 2008, and has remained active as a TMS clinician and researcher since then. She is Deputy Director of the new NIGMS-funded COBRE Center for Neuromodulation at Butler Hospital, as well as Director of the Center’s Neuromodulation and Neuroimaging Core. In addition to her leadership roles within CTMSS, Dr. Carpenter serves on the American Psychiatric Association (APA) Council on Research and she has published extensively on TMS and other neuromodulation treatments for depression.
Targeting Brain Circuits with TMS
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Targeting Brain Circuits with TMS
Presentation Overview:
- Describe how brain circuits drive TMS targets.
- Recommend appropriate modifications to clinical targets for patients who are not responding or worsening with TMS.
- Compare different circuit-based targets that may be more effective for different symptoms or different syndromes.
Date of Release: March 5, 2021
Date of Expiration: March 4, 2023
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
**As a reminder, you must be logged into the Clinical TMS dashboard to view the recording. If you are having trouble accessing the webinar, please refer to the appropriate access instructions below.
Member Webinar Access Instructions
Non-Member Webinar Access Instructions
SPEAKER: Shan Siddiqi, MD
Shan Siddiqi is an instructor of psychiatry at Harvard Medical School and Director of Psychiatric Neuromodulation Research at the new Center for Brain Circuit Therapeutics at Brigham & Women’s Hospital. He completed his general psychiatry residency at Washington University in St. Louis, a neuropsychiatry fellowship at McLean/Massachusetts General Hospital, and a research fellowship at the Berenson-Allen Center for Noninvasive Brain Stimulation. His research is focused on personalizing TMS targets using brain circuit mapping and clinical phenomenology.
Combination Treatment with Transcranial Magnetic Stimulation and Ketamine for Treatment-resistant Depression
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Combination Treatment with Transcranial Magnetic Stimulation and Ketamine for Treatment-resistant Depression
Presentation Overview:
- To understand the literature on the mechanisms of action supporting combination treatment with TMS and ketamine
- To identify clinical situation in which combination treatment with TMS and ketamine may be warranted.
- To recognize where combination treatment with TMS and ketamine may fit in a treatment algorithm for medication refractory depression.
Date of Release: February 5, 2021
Date of Expiration: February 4, 2023
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKER: C. Sophia Albott, MD
Dr. C. Sophia Albott is the Deputy Vice Chair for Research and an Assistant Professor in the Department of Psychiatry & Behavioral Sciences at the University of Minnesota. Her research focuses on novel interventions (ketamine, transcranial magnetic stimulation, cognitive training) for treating mood (depression) and trauma-related disorders (PTSD). She published the first study of repeated ketamine infusions in veterans with PTSD and currently leads the first randomized controlled trial of repeated ketamine infusions for comorbid PTSD and depression. Dr. Albott’s research uses neuroimaging techniques (MRI) to evaluate structural and functional brain abnormalities in trauma-related disorders (PTSD, depression, secondary traumatic stress). She also established and leads the Ketamine Registry of Minnesota (KaRMa) which is a joint venture between the University of Minnesota and Mayo Clinic tracking long-term outcomes of patients receiving ketamine for depression. She maintains a part-time clinic at the MHealth Outpatient Neuromodulation Clinic where she also participates in clinical research translating her work on the pathophysiological mechanisms underlying disordered responses to trauma. She has received awards from the NIH and the University of Minnesota Medical School, and is currently funded through a K23 Career Development Award from the National Institute of Mental Health.
**As a reminder, you must be logged into the Clinical TMS dashboard to view the recording. If you are having trouble accessing the webinar, please refer to the appropriate access instructions below.
Recent Advances in Noninvasive Brain Stimulation for Child and Adolescent Psychiatric Disorders
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Recent Advances in Noninvasive Brain Stimulation for Child and Adolescent Psychiatric Disorders
Presentation Overview:
- Demonstrate a working knowledge of noninvasive brain stimulation modalities and recent research with child and adolescent patients.
- Explain the different among single-pulses, paired-pulse, low frequency, high frequency, and theta burst stimulation in transcranial magnetic stimulation clinical work and research.
- Describe recent research focused on accelerated transcranial magnetic stimulation protocols.
Date of Release: January 8, 2021
Date of Expiration: January 7, 2023
Format: ON-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKER: Paul Croarkin, DO
Dr. Croarkin’s research program focuses on adapting and innovating brain stimulation interventions in children and adolescents. This includes biomarker work to optimize diagnostic practices and the delivery of brain based interventions such as transcranial magnetic stimulation. A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. Dr. Croarkin is a professor of psychiatry in the Mayo Clinic College of Medicine.
Acknowledgement of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.
Satisfactory Completion
Learners must complete an evaluation form to receive a certificate of completion. You must participate in the entire webinar as partial credit is not available. If you are seeking continuing education credit for a specialty not listed below, it is your responsibility to contact your licensing/certification board to determine course eligibility for your licensing/certification requirement.
Physicians
In support of improving patient care, this activity has been planned and implemented by Amedco LLC and the Clinical TMS Society. Amedco LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team. Credit Designation Statement – Amedco LLC designates this enduring activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Questions? Email Certificate@AmedcoEmail.com
An Update Regarding Using TMS for Smoking Cessation
Presentation Overview:
- Be familiar with the preclinical and clinical work over the past decade indicating the TMS might be helpful to treat smoking addiction.
- Understand the basic design of a recent clinical trial that led to FDA approval of deep TMS for smoking cessation.
- Be able to describe different issues involved in using TMS for smoking addiction in a clinical practice setting.
Date of Release: December 4, 2020
Date of Expiration: December 3, 2022
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKER: Mark George, MD
Dr. George first began studying the relationship between mind and brain, or brain/behavior relationships while he was an undergraduate philosophy student at Davidson College. He then received his medical degree from the Medical University of South Carolina in Charleston in 1985, where he continued with dual residencies in both neurology and psychiatry. He is board certified in both areas.
Following his residency training he completed serial research fellowships, first in England and then at the NIH. While he was at the Institute of Neurology, Queen Square, London, England (1989-90), he used the new tools of functional imaging (PET and SPECT) to investigate the brain regions involved in normal emotions and brain changes that occur in depression and mania. He was also lucky to be exposed to a brand new technology, transcranial magnetic stimulation (TMS).
He then moved to Washington, DC, working with Dr. Robert Post in the Biological Psychiatry Branch of the Intramural National Institute of Mental Health (NIMH). During his 4 years at NIMH he continued with brain imaging (now fMRI) and began using TMS as a probe of neuronal circuits regulating mood, and in clinical trials using TMS as an antidepressant. In 1993 while at the NIMH, he discovered that daily prefrontal rTMS over several weeks could treat depression. He has since worked to grow the science of TMS and other forms of brain stimulation, both in terms of how they work in the brain, and in critically evaluating their therapeutic applications.
He returned to MUSC in 1996 and created a research brain imaging center and the Brain Stimulation Division within the department of psychiatry, which he still directs. In June 1998 at MUSC, he also helped pioneer another new treatment for resistant depression, cervical vagus nerve stimulation (VNS). This was FDA approved in 2006. Most recently he was the PI on an international trial that resulted in TMS being FDA approved to help with smoking cessation.
Dr. George is thus a world expert in brain imaging and brain stimulation, particularly combining the two. He is the editor-in-chief of a new journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has served as the chief editor for 13 years now and this journal is the top in its field.
He has been continuously funded by NIH and other funding agencies since his fellowships. He has received both a NARSAD Young Investigator and Independent Investigator Award to pursue TMS research in depression. He has received numerous international awards including the NARSAD Klerman Award (2000), NARSAD Falcone Award (2008) and the Lifetime Achievement Award (2007) given by the World Federation of Societies of Biological Psychiatry (WFSBP). He is on several editorial review boards and NIH study sections, has published over 500 scientific articles or book chapters, and has written or edited 6 books.
When he is not working he enjoys gardening, kite surfing, hiking and biking, and dreaming about the future of mankind and where neuroscience is headed...
Acknowledgement of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.
Pearls and Pitfalls for Launching into Clinical Research
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Pearls and Pitfalls for Launching into Clinical Research
Presentation Overview:
1. Why its important to conduct research properly
2. How we chose topics to be covered
3. IRB process
4. Building a database
5. Meta-Analysis/Review
6. How to prepare an abstract
7. How to determine your research question
Date of Release: October 9, 2020
Date of Expiration: October 8, 2022
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
SPEAKERS: F. Andrew Kozel, MD, MSCR, Andrew Leuchter, MD, Paul Croarkin, DO, MS, Angela Leah Phillips, LICSW, PhD
F. Andrew Kozel, MD, MSCR - Dr. Kozel is the Director of the TMS Clinic and Staff Psychiatrist in Mental Health and Behavioral Sciences (MH&BS) and Associate Investigator in the HSR&D Center of Innovation on Disability and Rehabilitation Research (CINDRR) at the James A. Haley Veteran's hospital, as well as Associate Professor, Department of Psychiatry and Behavioral Sciences, University of South Florida. Dr. Kozel's research uses brain imaging and brain stimulation to better understand and treat neuropsychiatric disorders with the focus of improving the lives of patients with these disorders.
Andrew F. Leuchter, MD, is a Professor of Psychiatry at the Semel Institute for Neuroscience and Human Behavior, Executive Vice Chair of the Department of Psychiatry and Biobehavioral Sciences, and Associate Director of the Semel Institute. He also is Director of the Neuromodulation Division at the Semel Institute. Dr. Leuchter is a graduate of Stanford University and the Baylor College of Medicine who joined the UCLA faculty in 1986.
An expert on the treatment of mood disorders, Dr. Leuchter directs the Transcranial Magnetic Stimulation (TMS) Clinical and Research Service. This is one of the largest academic TMS program in the country, which performs more than 6,000 treatments each year for patients with depression, pain, Obsessive-Compulsive Disorder, tinnitus, and other neuropsychiatric illness. He performs research to enhance TMS treatment effectiveness, as well as clinical trials to improve treatment of depression, Post-Traumatic Stress Disorder (PTSD), and Attention-Deficit/Hyperactivity Disorder (ADHD). Dr. Leuchter’s research aims to develop novel treatment strategies and uses brain-imaging techniques, such as quantitative electroencephalography (qEEG) and magnetic resonance imaging (MRI) to examine brain function and predict which treatments are most likely to benefit individual patients.
Dr. Leuchter has authored over 150 scientific articles on topics including neuromodulation for the treatment of depression, EEG biomarkers to guide treatment of neuropsychiatric illness, and theories of antidepressant action. He teaches internationally on TMS and other neuromodulation methods, and received the 2019 Outstanding Research Mentor Award from the Semel Institute.
Paul Croarkin, DO, MS' research program focuses on adapting and innovating brain stimulation interventions in children and adolescents. This includes biomarker work to optimize diagnostic practices and the delivery of brain based interventions such as transcranial magnetic stimulation. A central theme focuses on the role of gamma-aminobutyric acid (GABA) and glutamate neurotransmitter systems in early-onset mood disorders with the goal of informing safer and more effective biologic treatments. Dr. Croarkin is a professor of psychiatry in the Mayo Clinic College of Medicine.
Angela Phillips, LICSW, PhD currently has a dual postdoctoral role with the Stanford Brain Stimulation Lab, and the VA, Palo Alto, CA, USA. She obtained her BA from the University of North Carolina in Clinical Psychology, followed by her MSW and clinical licensure in Mental Health Practice, and PhD in Nursing Science, from the University of Washington. Angela has worked across inpatient and outpatient clinical psychiatry for over a decade with research interests focusing on neuromodulatory psychiatric and mental health interventions, including novel non-invasive brain stimulation methods, and combined psychotherapeutic interventions for complex neurological and neuropsychiatric disorders.
Neuro-Cardiac-Guided TMS (NCG-TMS) to Target the Depression Network: Possibilities for rTMS Treatment Stratification?
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: Neuro-Cardiac-Guided TMS (NCG-TMS) to target the depression network: Possibilities for rTMS treatment stratification?
Learning objectives:
1. What is the difference between Precision Psychiatry and Stratified Psychiatry;
2. The relation between the frontal-vagal network, depression and various neuromodulation treatments;
3. How to use NCG-TMS to stratify between two known treatment locations (5 cm. vs. Beam-F3) to individualize rTMS treatment.
Date of Release: September 4, 2020
Date of Exipration: September 3, 2022
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
*Registered attendees will receive access to the on-demand video recording on Friday, September 4, 2020. You will receive an email notification on Friday with instructions on how to access the video. You may register for the on-demand webinar at any time after the live webinar.
Speaker: Martijn Arns, QEEG-D, BCN
Martijn Arns graduated in the late 90’s as a biological psychologist at the Radboud University in Nijmegen and did his PhD at Utrecht University on the topic of 'EEG-based personalized medicine for ADHD and depression' and is specialized in neurobiological aspects of ADHD and depression.
In 2001 he founded Research Institute Brainclinics, now part of the non-profit Brainclinics Foundation, as an independent research institute, where he further specializes in advancing the understanding of psychiatric disorders through brain imaging and optimizing neuromodulation treatments such as rTMS and neurofeedback.
In addition, Martijn is assistant professor at the Amsterdam UMC / University of Amsterdam, department of Psychiatry (location AMC).
Acknowledgement of Financial and/or In-Kind Commercial Support
No financial or in-kind commercial support was received for this educational activity.
TMS Practice at the Time of COVID-19
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: TMS Practice at the Time of COVID-19
Learning objectives:
1. State five (5) forms of personal protective equipment and when to use it;
2. Understand changes in patient flow and barriers to prevent exposures;
3. Develop a protocol for suspected or confirmed exposures or infection in patients and staff.
Date of Release: July 17, 2020
Date of Expiration: July 16, 2022
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
*Registered attendees will receive access to the on-demand video recording on Friday, July 17, 2020. You will receive an email notification on Friday with instructions on how to access the video. You may register for the on-demand webinar at any time after the live webinar.
Panelists:
Richard Bermudes, MD
Dr. Bermudes is a Board Certified Psychiatrist and the Chief Medical Officer of TMS Health Solutions. He completed medical school at the University of California, San Diego and residency training in Psychiatry and Family Medicine at the University of Cincinnati.
Dr. Bermudes founded TMS Health Solutions (TMS HS) in 2007, a group practice with over 30 interventional-neuropsychiatrists in California. TMS HS has a number of clinical programs and provides medication management, psychotherapy, ECT, TMS and Esketamine services.
He co-wrote and co-edited “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice1, a book with key research findings on TMS as well as its potential to be used for other conditions such as OCD, PTSD, Adolescent Depression and mild dementia.
Dr. Bermudes is a founding member of the Clinical TMS Society. He chaired the groupʻs first annual meeting in 2013 and was elected as its president in 2015, serving for two years. He currently serves on the Board of Directors and co-chairs the Insurance Committee.
1 Bermudes, Richard A., Karl I. Lanocha, and Philip G. Janicak, eds. Transcranial magnetic stimulation: clinical applications for psychiatric practice. American psychiatric pub, 2017.
Kevin Kinback, MD
Dr. Kinback trained in both medicine and psychiatry in Southern California at Loma Linda University, where he still serves as Assistant Clinical Professor, as well as Johns Hopkins. He was one of the first to adopt TMS in 2008, and has trained on several devices. Dr. Kinback participated in early clinical trials with two TMS device companies and has taught in the PULSES course.
Very active with the TMS Society, Dr. Kinback has served on the Board of Directors the past 5 years, has edited the Magnet Newsletter, and chaired the Insurance Committee for several years. As a very strong advocate for patient care and TMS education, he chaired an APA workshop in San Diego called “Starting a TMS Practice, What I Wish I Would Have Known.” Dr. Kinback remains active on the Legal, Business & Ethics, as well as the Outreach Committee, in addition to running his private practice, Advanced TMS Center in Orange County.
Dr. Kinback has a background in engineering and construction, as well as disaster medicine, having served on Federal Disaster Medical Assistance Teams (DMAT), as well as decades with the Red Cross, Civil Defense, EMS services. These experiences bring a unique and useful perspective to coping with the current pandemic crisis.
William Sauvé, MD
Dr. William Sauvé commenced his career in psychiatry with the U.S. Marines followed by service as a Division Officer of inpatient psychiatry at the Naval Medical Center of San Diego. After his years of military practice, Dr. Sauvé relocated to Richmond, Virginia where he started a private psychiatric practice. He joined Greenbrook TMS NeuroHealth Centers as Medical Director of our Rockville, Richmond and Charlottesville locations in January 2014. He also serves as a staff psychiatrist in Tysons Corner.
Lauren Valencia, LCSW
Lauren has worked with TMS patients for 7 years as a TMS Coordinator and Therapist for the Neuroscience and TMS Treatment Centers in Nashville, TN. Currently she coordinates two offices with three TMS devices.
In the past Lauren has spoken at Clinical TMS Society Annual Meetings & taught as a member of the PULSES faculty during her time on the CTMSS Education Committee. She is also a co-author of Train Your Brain, the online TMS Workbook. Lauren utilizes aspects of CBT, DBT, and Motivational Interviewing to work with patients strengths and develop treatment goals relevant to living a fulfilling life.
Lauren graduated with her Masters of Science in Social Work from the University of Tennessee College Of Social Work in 2013. Prior to becoming an Clinical Social Worker Lauren received her B.S. in Psychology and Criminology from Florida State University. Lauren's previous experiences include working with vulnerable populations in the Veterans Affairs System, Alive Hospice, and Children's Home Society of Florida.
The Frontal Pole: An Emerging TMS Treatment Target for Drug and Alcohol use Disorders
You’re invited to join the Clinical TMS Society for this installment of our Grand Round Webinar Series: The Frontal Pole: An Emerging TMS Treatment Target for Drug and Alcohol Use Disorders
Learning objectives:
1. Learn techniques which promote comfort, compliance, and feasibility of frontal polar TMS;
2. Learn the scientific basis for choosing the frontal pole as a target;
3. Learn about recent studies in cocaine and alcohol users that have used this target.
Date of Release: June 5, 2020
Date of Expiration: June 4, 2022
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Colleen Hanlon, PhD
Dr. Hanlon is a professor in the Department of Cancer Biology at Wake Forest University Health Sciences. She received her undergraduate degree at the University of Florida, Ph.D. in Neurobiology from Duke University, did a postdoctoral fellowship in Addiction with Linda J. Porrino, Ph.D., and was trained to do TMS from Mark S. George, M.D. at the Medical University of South Carolina – wherein she spent the majority of her career to date. Now at Wake Forest University, she leads the Clinical Neuromodulation Program which is devoted to understanding the basic neurobiological effects of brain stimulation techniques (e.g. TMS, TDCS, Ultrasound) as well as developing evidence-based therapeutic strategies for smoking, alcohol use disorders, and pain. She collaborates with teams of preclinical researchers in the Department of Physiology and Pharmacology and clinician scientists in the Departments of Neurology, Psychiatry, and Anesthesiology/pain management. She was given an Early Career Investigator award from the National Institute of Drug Abuse in 2011 and is the senior author on the first “Consensus Paper” published by a group of over 70 scientists from over 10 countries outlining the path forward for Non-Invasive Therapeutic Development for Addiction.
In addition to serving as a principal investigator on several NIH-funded awards devoted to brain imaging and brain stimulation, she is also an eager teacher - participating in the research training and education community at both a local level (serving as a mentor to over 50 medical, graduate, post-graduate, and fellowship trainees since 2005 on a national and international scale) and national level. She directed the Advanced TMS Training Course sponsored by the National Center for Neuromodulation for Rehabilitation, and lead their social medial research dissemination efforts through curation of their website and social media pages. She has also lead an annual addiction outreach event at the College of Problems on Drug Dependence (CPDD) meeting (2015-2019), served on the Liaison Committee (2016-2019) and the Education and Training Committee (2019-present) for the American College of Neuropsychopharmacology, Grassroots Advocacy Team for the Society for Neuroscience (2017-2019), Chair of the Education Outreach and Public Policy Committee for CPDD (2017-2019), ad hoc participation in over 20 NIH study sections, and serving as a standing member of NIH NPAS study section (effective 10/2018).
TMS Mechanisms of Action: Complexity Simplified
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: TMS Mechanisms of Action: Complexity Simplified
Learning objectives:
1. Where TMS is applied, how it is applied and what is the underlying brain activity will determine its effects;
2. Could various stimulation parameters lead to different outcomes;
3. What is the next step in optimizing TMS’ clinical outcomes.
Date of Release: April 10, 2020
Date of Expiration: April 9, 2022
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Ziad Nahas, MD
Dr. Nahas received his Medical Degree from Saint Joseph University in Lebanon. He then completed an internship in Psychiatry at L’Institut Paul Silvadon, a Lacanian day-hospital, and Hopital Charles Foix, both in Paris France. He moved to Houston Texas in 1993 as a resident in Psychiatry at Baylor College of Medicine. Dr. Nahas also attended the Houston-Galveston Psychoanalytic Institute’s psychodynamic psychotherapy course. He later joined the Medical University of South Carolina (MUSC) in 1997 where he completed a research fellowship in Functional Neuroimaging and Psychopharmacology and a Master of Science in Clinical Research. He was a faculty member from 1999 to 2011 with a specific focus on research in mood disorders and brain stimulation. From Summer 2011 to Spring 2017, Dr. Nahas was the Chair of the Department of Psychiatry at the American University of Beirut Medical Center (AUBMC) where he helped develop the department's clinical, education and research portfolio. In 2017, Dr Nahas joined the Department of Psychiatry at the University of Minnesota where he serves as the vice chair for clinical affairs and director of the mood disorders and interventional psychiatry programs.
In addition to his scientific and academic contributions, Dr. Nahas has been a strong advocate for the parity of mental health care coverage in Lebanon. He co-founded Embrace, a Non-Profit Organization to fight stigma associated with mental illness and provide financial support for patients who cannot afford the cost of their treatments. Embrace has launched the first Suicide Prevention Help Line in the Middle East.
COVID-19: Providing Quality Care and Safe Practices for HCP at TMS Centers
You’re invited to join the Clinical TMS Society for this special installment of our Grand Round Webinar Series: COVID-19: Providing Quality Care and Safe Practices for HCP at TMS Centers
Learning Objectives:
1. Review COVID-19 Transmission, Symptoms, Disease Progession and the Dynamics of Community Transmission;
2. The COVID-19 Evaluation Tool: Screening and Evaluating COVID-19 severity at TMS Health Centers;
3. Safe Practices for Health Care Personnel;
4. Clinical Examples: Managing Psychiatric Conditions and COVID-19 Risk and symptoms of COVID-19.
Date: Thursday, March 19, 2020
Time: 8:00 pm EDT, 5:00 pm PDT
Format: On-Demand
Cost: Members: FREE | Non-members $50 | Student Members FREE
*The recording for this webinar will be available to registered attendees on Friday, March 20, 2020.
Panel Discussion with the following:
Richard Bermudes, MD
Richard Bermudes, MD earned his medical degree from the University of California, San Diego and completed his residency training in psychiatry and in family medicine at the University of Cincinnati. He is board certified by the American Board of Neurology and Psychiatry and completed a fellowship in cognitive therapy and cognitive therapy supervision at the Beck Institute for Cognitive Therapy and Research in Philadelphia, Pennsylvania. Dr. Bermudes has 20 years’ experience caring for patients and is the chief medical officer of TMS Health Solutions, an organization he founded in 2007. He serves as the practice’s Medical Director and is an expert on TMS practice organization and policy development. In February 2010, Dr. Bermudes was the first provider of TMS therapy for depression in the Sacramento region. He recently co-wrote and edited Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice published by American Psychiatric Association Publishing, 2018.
John Onate, MD
Dr. Onate practices both Internal Medicine and Psychiatry at the Sacramento County Health Center, where he currently is the director of Integrated Behavioral Health. As a faculty member at the University of California Davis School of Medicine he supervises Psychiatry, Combined Internal Medicine and General Internal Medicine residents; addressing the coordination of medical care in uninsured and indigent patients with mental illness and substance disorders. He is a recipient of the American Psychiatric Association’s Nancy C.A. Roeske, M.D., Certificate of Recognition for Excellence in Medical Student Education. He has published several articles and book chapters in the field of primary care preventative health and psychiatry. He has spoken nationally at on the subject of integration, collaboration in medical and mental health care, addiction medicine, sports psychiatry, and on exercise as a treatment for depression. Dr. Onate has appeared on the PBS medical program “Second Opinion”. He is strongly interested in the collaboration and integration of psychiatric care and substance abuse treatment in primary care, HIV medicine and Hepatitis C and exercise in the treatment of mental illness. He is the faculty advisor for the UCDSOM Chapter of the Gold Humanism Honor Society.
Education
1996 Biology, University of Southern Mississippi
2000 University of Mississippi School of Medicine
Post Graduate Medical Training
2005 Combined Internal Medicine and Psychiatry, Rush University Medical Center, Chicago, IL
Board Certification
ABIM-Internal Medicine
ABPN-Psychiatry
Using TMS and TBS as Treatment for PTSD
Learning objectives:
1. Describe brain circuitry involved in posttraumatic stress disorders;
2. Discuss the literature to date using transcranial magnetic stimulation for PTSD;
3. Demonstrate understanding of potential utility in short and long-term outcomes of theta burst for PTSD.
Date of Release: March 6, 2020
Date of Expiration: March 5, 2022
Format: ON-DEMAND
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Noah S. Philip, MD
Noah S. Philip, MD received his BSc from McGill University, and his MD from Albany Medical College where he graduated AOA and with a Distinction in the Study of Biomedical Ethics. He completed his psychiatry residency training at Brown University, followed by an NIH-sponsored T32 Fellowship and a Neuromodulation Fellowship at Brown.
Dr. Philip is an Associate Professor of Psychiatry and Human Behavior at the Alpert Medical School of Brown University. He is the founding Director of Psychiatric Neuromodulation at the Providence VA Medical Center, and is Lead for Affective & Cognitive Research at the VA RR&D Center for Neurorestoration and Neurotechnology.
Dr. Philip’s laboratory uses new and emerging technologies to understand and treat serious psychiatric disorders, such as posttraumatic stress disorder, major depression, and suicidality. Methods used integrate non-invasive brain stimulation, focused ultrasound, virtual reality, machine leaning and neuroimaging. Dr. Philip's research has been featured in the American Journal of Psychiatry, Biological Psychiatry, and the National Neuroscience Curriculum Initiative.
Dr. Philip has received numerous awards and recognition from various national organizations, and is funded through independent grants from the VA, NIMH, NIDA, Department of Defense, as well as industry and small-business collaborations. Dr. Philip also plays a significant training and mentoring role at Brown, where he co-directs the psychiatry resident research track, and serves as a mentor locally and through many national organizations.
Stanford Accelerated Intelligent Neuromodulation Therapy
Stanford Accelerated Intelligent Neuromodulation Therapy
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Stanford Accelerated Intelligent Neuromodulation Therapy
Learning objectives:
1. Introduce the concept of interventional psychiatry and the history of therapeutic brain stimulation in psychiatry.
2. Establish parallels between current approaches in psychiatry with those employed by neurologists, cardiologists, and radiologists.
3. Discuss a framework for further development of novel therapeutics for treatment-resistant psychiatric conditions.
Date of Release: February 7, 2020
Date of Expiration: February 6, 2022
Format: On-Demand
Cost: Due to the cancellation of our November 2020 Grand Round Webinar, this recoding is available to both members and non-members for FREE.
*Please note, this offer does NOT include CME. If you would like to view the recording AND collect CME, please REGISTER HERE.
Speaker: Nolan Williams, MD
Dr. Williams is an Assistant Professor within the Department of Psychiatry and Behavioral Sciences and the Director of the Stanford Brain Stimulation Lab. Dr. Williams has a broad background in neuropsychiatry and is double board-certified in both neurology and psychiatry. In addition, he has specific training and clinical expertise in the development of brain stimulation methodologies under Mark George, MD. Themes of his work include (a) examining the use of spaced learning theory in the application of neurostimulation techniques, (b) development and mechanistic understanding of rapid-acting antidepressants, and (c) identifying objective biomarkers that predict neuromodulation responses in treatment-resistant neuropsychiatric conditions. He has published papers in high impact peer-reviewed journals including Brain, American Journal of Psychiatry, and the Proceedings of the National Academy of Science. He has also contributed to two reviews related to novel therapeutics for neuropsychiatric conditions that have been published in the Journal of Clinical Investigation and Current Opinion in Neurobiology, which are both highly cited. Results from his studies have gained widespread attention in journals such as Science and New England Journal of Medicine Journal Watch as well as in the popular press and have been featured in various news sources including Time, Smithsonian, and Newsweek. Dr. Williams received two NARSAD Young Investigator Awards in 2016 and 2018 along with the 2019 Gerald R. Klerman Award. He started the Stanford Brain Stimulation Lab in 2015. He has received several merit-based travel awards to attend and present at the annual meetings for American College of Neuropharmacology, Society of Biological Psychiatry, the American Academy of Neurology and the American Neuropsychiatric Association.
NEW CTMSS Education Slide Deck: Transcranial Magnetic Stimulation (TMS) - An Introduction
NEW CTMSS Education Slide Deck: Transcranial Magnetic Stimulation (TMS) - An Introduction
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
NEW CTMSS Education Slide Deck: Transcranial Magnetic Stimulation (TMS) - An Introduction
Learning objectives:
1. Understand the history of and science behind Transcranial Magnetic Stimulation (TMS);
2. Understand indications and contraindications of TMS;
3. Understand the pivotal literature on TMS in the treatment of depression and OCD;
4. Understand the risks and side effects of TMS.
*At the conclusion of this Grand Round webinar, the Community Education Slide Deck will be made available to Clinical TMS Society members for educational purposes by completing the Member User Agreement.
Date of Release: January 7, 2020
Date of Expiration: January 6, 2022
Time: 8:00 pm EST, 5:00 pm PST
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speaker: Mark George, MD
Dr. George is a world expert in brain stimulation, and depression, and is the editor-in-chief of a new journal he co-launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has been continuously funded by NIH and other funding agencies since his fellowships. He performed early pioneering work with TMS for depression, and combining TMS with brain imaging. After his research fellowship at the NIMH intramural program where he first delivered TMS for depression, he received both a NARSAD Young Investigator and Independent Investigator Award to further pursue TMS research in depression. He has received numerous international awards including the NARSAD Klerman Award (2000), NARSAD Falcone Award (2008) and the Lifetime Achievement Award (2007) given by the World Federation of Societies of Biological Psychiatry (WFSBP). In 2009 US News and World Report named him one of 14 ‘medical pioneers who are not holding back’. He has published over 500 scientific articles or book chapters, and has written or edited 6 books. He lives on the beach, kite surfs, raises bees and chickens, and recently gathered TMS motor thresholds in zero-gravity.
Neurocognitive Studies in Depersonalisation Disorder: A possible indication for rTMS?
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
Neurocognitve Studies in Depersonalisation Disorder: A possible indication of rTMS?
Learning objectives:
1. To recognize the clinical features of depersonalization/derealization;
2. Understand the possible neurophysiological basis for emotional numbing and its relationship to DP/DR;
3. To be familiar with neuroimaging research in DP;
4. To understand the theoretical basis for rTMS as a possible treatment for DP/DR.
Date of Release: December 6, 2019
Date of Completion: December 5, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Anthony David, MD
Professor Anthony David, is Director, University College London Institute of Mental Health.
Professor David graduated in medicine from Glasgow University in 1980 and trained in neurology before entering psychiatry at the Maudsley Hospital, London. He also has a Masters degree in Cognitive Neuropsychology. He was an honorary consultant at the Maudsley from 1990-2018 and was awarded a personal chair from the Institute of Psychiatry, King’s College London in 1996. He was Vice Dean for Academic Psychiatry at the IoPPN in 2013-8.
Professor David has a wide and diverse range of research interests including schizophrenia, neuropsychiatry, medically unexplained syndromes and neuroimaging – both structural and functional. He is especially interested in the concept of insight in schizophrenia and depersonalization disorder. Professor David is a Fellow of the Royal College of Physicians, the Royal College of Psychiatrists and the Academy of Medical Sciences. He is a member of the Experimental Psychology Society and a founder member of both the British Neuropsychological Society and British Neuropsychiatry Association and was Chairman to the latter from 2004-7. He delivered the inaugural “King’s Lectures” in 2018 on the topic “Psychiatry, Science and Society”.
Individualized TMS Target Selection: Clinical Outcomes, Mechanisms of Action and Predictors of Response
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
Individualized TMS Target Selection: Clinical Outcomes, Mechanisms of Action and Predictors of Response
Learning objectives:
1. Be able to understand the potential benefits of individualized Neuronavigated TMS;
2. Identify circuit-based predictors of TMS response;
3. Identify the circuit-based mechanisms of action of TMS antidepressant effects.
Date of Release: November 8, 2019
Date of Completion: November 7, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Joan Camprodon, MD, PhD
Dr. Camprodon is Chief of the Division of Neuropsychiatry at Massachusetts General Hospital and Assistant Professor of Psychiatry at Harvard Medical School. Clinically, he is the founding director of the MGH Transcranial Magnetic Stimulation (TMS) clinical service, a member of the Psychiatric Neurosurgery Committee and an attending physician in the departments of Psychiatry (Neuropsychiatry) and Neurology (Cognitive and Behavioral Neurology). He is board-certified in Psychiatry and Behavioral Neurology & Neuropsychiatry.
Scientifically, he directs the Laboratory for Neuropsychiatry and Neuromodulation. His research uses multimodal combinations of neuroimaging and brain stimulation to investigate neural circuitry and plasticity in a translational manner. His laboratory works with a wide range of noninvasive and invasive neuromodulation techniques including transcranial current stimulation (tCS), transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT) and deep brain stimulation (DBS) among others. He also uses functional and structural MRI, EEG and innovative simultaneous combinations of TMS and tDCS with neuroimaging. Dr. Camprodon is interested in understanding basic circuit properties of human neural networks and how maladaptive plastic changes lead to neuropsychiatric disorders. Critical efforts are geared towards applying the paradigms and methods of human systems neuroscience to develop high-impact clinical tools, identify targets for therapeutic action and design individualized image-guided neuromodulation treatments.
What to do when Patients are not Responding to TMS
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
What to do when Patients are not Responding to TMS
Learning objectives:
- Be able to identify which TMS parameters can safely be changed
- Be able to identify which TMS parameter changes could potentially change TMS response
- Identify ways of augmenting TMS treatment to improve response
Date of Release: October 4, 2019
Date of Expiration: October 3, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Tracy Barbour, MD
Dr. Tracy Barbour is the Medial Director of the Massachusetts General Hospital Transcranial Magnetic Stimulation (TMS) clinical service, and an attending physician in the Department of Psychiatry. Dr. Barbour’s research interests focus on addressing ways of improving treatment outcomes using Transcranial Magnetic Stimulation (TMS) through individualized treatment planning. Dr. Barbour received her medical degree from Wayne State University School of Medicine in Detroit, Michigan, and completed psychiatry residency at MGH/McLean combined residency program. During residency, she served as the chief resident of McLean Hospital’s Clinical Evaluation Center. Following residency, Dr. Barbour was awarded the competitive Dupont-Warren Fellowship from Harvard Medical School, to learn advanced methods in neuroimaging and neuroscience research. Recently, Dr. Barbour was awarded a nationally prestigious NARSAD Young Investigator Award from the Brain and Behavior Foundation.
The Fundamentals of TMS Practice Management
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
The Fundamentals of TMS Practice Management
Learning objectives:
1. Describe a framework to evaluate TMS systems
2. Review key clinical operations and procedures that support patient access to TMS therapy
3. Describe practice standards and quality metrics for TMS practices
Date of Release: September 6, 2019
Time: 1 hour
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Richard Bermudes, MD
Richard Bermudes, M.D. earned his medical degree from the University of California, San Diego and completed his residency training in psychiatry and in family medicine at the University of Cincinnati. He is board certified by the American Board of Neurology and Psychiatry and completed a fellowship in cognitive therapy and cognitive therapy supervision at the Beck Institute for Cognitive Therapy and Research in Philadelphia, Pennsylvania. Dr. Bermudes has 20 years’ experience caring for patients and is the chief medical officer of TMS Health Solutions, an organization he founded in 2007. He serves as the practice’s Medical Director and is an expert on TMS practice organization and policy development. In February 2010, Dr. Bermudes was the first provider of TMS therapy for depression in the Sacramento region. He recently co-wrote and edited Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice published by American Psychiatric Association Publishing, 2018.
How to apply TMS for Pain and Headache Management- Mechanisms, Outcome Evidence and Treatment Guidelines
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
How to apply TMS for Pain and Headache Management-Mechanisms, Outcome Evidence and Treatment Guidelines
Learning objectives:
1. Learners will review the underlying analgesic mechanisms;
2. Discuss the current outcome evidence of TMS for pain and headaches;
3. Review the latest consensus treatment guideline and discuss how we can further promote the clinical implementation of TMS outside the regime of psychiatry.
Date of Release: July 5, 2019
Date of Completion: July 4, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Albert Leung, MD
Albert Y. Leung, M.D., is a Professor of Anesthesiology and Pain Medicine at the University of California, San Diego, School of Medicine. He is the Director, Center for Pain and Headache Research, and Center for TMS at the VA San Diego Healthcare System. Dr. Leung is currently leading a 30-member multinational multidisciplinary expert panel in reviewing outcomes and providing treatment recommendation for TMS in pain and headache management. His single/multicenter studies focus on assessing the mechanisms and effectiveness of non-invasive brain and peripheral stimulation for nerve function restoration and headache/pain relief. He founded the first TMS clinical unit for pain and headache treatment at his institution a decade ago. His research received multiple funding awards from the National Institutes of Health (NIH), the Department of Defense (DOD), and the Veteran Affairs Office of Research and Development (ORD).
Innovations in rTMS Treatment
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
Innovations in rTMS Treatment
Learning objectives:
- Learners will be able to identify conventional rTMS strategies to treat medication resistance depression.
- Learners will be able to identify novel brain mechanisms that may help to identify treatment resistant depression.
- Learners will be able to identify novel rTMS treatment strategies to treat depression when conventional approaches do not work.
Date of Release: June 7, 2019
Date of Completion: June 6, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Jeff Daskalakis, MD, PhD
Jeff Daskalakis is a Professor of Psychiatry at University of Toronto. He is presently the Temerty Chair in Therapeutic Brain Intervention and chief of the General Adult Psychiatry and Health Systems Division at CAMH. The Temerty Centre uses magnetic brain stimulation to study the role of cortical inhibition and plasticity as potential pathophysiological mechanisms in schizophrenia, depression and obsessive compulsive disorder. Dr. Daskalakis also conducts treatment studies using repetitive transcranial magnetic brain stimulation (rTMS) and magnetic seizure therapy (MST) for refractory symptoms in these disorders. He holds or has held NARSAD, CIHR, Brain Canada and NIMH operating awards and grants. He has also been awarded the Samarthji Lal Award in Mental Health Research from the Graham Boeckh Foundation. He is also a member of the Brain and Behavior Research Foundation Scientific Council. Finally, he has over 320 peer-reviewed publications and is an editorial board member for Biological Psychiatry and an Associate Editor for Clinical Neurophysiology.
TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
TMS as a Translational Tool to Bridge Pathophysiology to Novel Interventions in Autism Spectrum Disorder
Learning objectives:
1. Review the findings of studies using TMS to probe the mechanisms of intracortical inhibition and plasticity in autism spectrum disorder (ASD).
2. Describe how TMS can be used to induce long-term changes in brain network functioning and potentially treat core and associated symptoms of ASD and related disorders.
3. Identify a number of potential network targets where applying TMS may be effective for reducing specific targeted symptom domains.
Release Date: May 10, 2019
Date of Expiration: May 9, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Dr. Lindsay Oberman, PhD
Dr. Lindsay Oberman, PhD is the Clinical Program Leader for TMS trials at the Center for Neuroscience and Regenerative Medicine with a faculty appointment in the Department of Medical and Clinical Psychology at the Uniformed Services University (USU). She is also a “Special Volunteer” in the Noninvasive Neuromodulation Unit, National Institute of Mental Health, National Institutes of Health. The focus of her research is to investigate the mechanisms that contribute to the function and dysfunction of neural systems involved in the core symptoms of complex neuropsychiatric disorders with the ultimate goal of developing novel treatment strategies. Over the past 16 years working in this field, she has gained an appreciation for the complexity of the pathophysiology of behaviorally defined disorders. Thus, she has recently shifted her focus to identifying and modifying neural circuits associated with specific cross diagnostic behavioral domains (such as mood regulation, sensory processing, social cognition, language processing, and executive functioning/cognitive control) in order to better target the symptoms that affect the quality of life of individuals with neuropsychiatric and neurodevelopmental disorders including autism spectrum disorder, traumatic brain injury, and post-traumatic stress disorder.
The Fundamentals of TMS Practice Management
Your registration fee will be refunded, please allow 7-10 business to see the refund in your account.
Thank you and if you have any questions, please email info@clinicaltmssociety.org
WEBINAR CANCELLED: The Fundamentals of TMS Practice Management
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
The Fundamentals of TMS Practice Management
Learning objectives:
1. Describe a framework to evaluate TMS systems
2. Understand the key components of training for providers and technicians
3. Describe the key components of TMS quality improvement program
4. Review the critical steps of the revenue cycle associated with TMS practices
Date: Tuesday, April, 2, 2019
Format: LIVE
Cost: Members: $25 | Non-members $50 | Student Members FREE
Speakers: Richard Bermudes, MD
Richard Bermudes, M.D. earned his medical degree from the University of California, San Diego and completed his residency training in psychiatry and in family medicine at the University of Cincinnati. He is board certified by the American Board of Neurology and Psychiatry and completed a fellowship in cognitive therapy and cognitive therapy supervision at the Beck Institute for Cognitive Therapy and Research in Philadelphia, Pennsylvania. Dr. Bermudes has 20 years’ experience caring for patients and is the chief medical officer of TMS Health Solutions, an organization he founded in 2007. He serves as the practice’s Medical Director and is an expert on TMS practice organization and policy development. In February 2010, Dr. Bermudes was the first provider of TMS therapy for depression in the Sacramento region. He recently co-wrote and edited Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice published by American Psychiatric Association Publishing, 2018.
Towards Personalized Neuromodulation
1. Learners be able to describe patterns of clinical response to TMS
2.Learners will be able to identify individualized TMS targeting approaches based on patient-specific symptoms
3. Learners will be able to understand investigational approaches to individualized brain mapping for TMS targeting
Date of Release: March 15, 2019
Date of Expiration: March 14, 2021
Format: On-Demand
Cost: Members: $25 | Non-members $50
Speakers: Shan Siddiqi, MD
Dr. Siddiqi is a neuropsychiatrist and the Sidney R. Baer Fellow in Clinical Neuroscience at Harvard Medical School and the Berenson-Allen Center for Noninvasive Brain Stimulation. Clinically, his interests include behavioral effects of focal brain lesions and therapeutic brain stimulation. His research is focused on developing better methods for individualizing neuromodulatory treatments based on functional MRI (fMRI) and clinical phenomenology. He has been involved in several trials involving individualized brain network mapping to target TMS for depression associated with traumatic brain injury. He is now working on developing computational models for using brain stimulation to explain human behavior. This includes mapping of human emotional circuits via novel approaches to data acquired from functional MRI, TMS, deep brain stimulation, and brain lesions. He uses this approach to develop individualized brain stimulation targets based on patient-specific symptoms and imaging findings.
Accelerated rTMS: A Potential Treatment Approach to Alleviate Depression?
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series:
Accelerated rTMS: A Potential Treatment Approach to Alleviate Depression?
Learning objectives:
1. Learners will know the most updated literature on accelerated rTMS paradigms and major depression.
2. Learners will have better insights on the neurobiological effects of accelerated rTMS protocols applied in depressed patients.
3. Learners will be able to state the risks and benefits of accelerated rTMS and accelerated iTBS paradigms for (treatment-resistant) major depression.
4. Learners will be able to have improved risk and benefit discussions with (treatment-resistant) depressed patients who are interested in rTMS treatment.
Date: Tuesday, January 15, 2019
Format: On-Demand
Date of Release: January 16, 2019
Date of Expiration: January 15, 2021
Cost: Members: $25 | Non-members $50
Speakers: Chris Baeken, MD, PhD
Chris Baeken, MD, PhD is full time associate professor at the University hospital of the Ghent University, and he is part-time associate professor affiliated with the University hospital of the Free University of Brussels, both in Belgium. As a psychiatrist his main interests are within the neurobiological field of Affective Disorders. To gain more insight in the underlying mechanisms of emotional brain processes in the ‘healthy’ as well as in the ‘mentally affected’ human brain, brain-imaging paradigms (MRI, fMRI, (S)PET,….) are used with or without the combination of neuromodulation techniques, such as rTMS and tDCS. His scientific contributions to clinical neuroscience is shown by over 200 peer-refereed scientific publications, mainly on clinical treatment, brain stimulation and neurobiology. His work has received very high international recognition from peers as can be judged from over 3000 citations to his work and an H-index of 32 (Google Scholar).
Review of Antenatal Depression and TMS: Is it a Treatment Option?
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds On-Demand Webinar:
Review of Antenatal Depression and TMS: Is it a Treatment Option?
Learning objectives:
- Learners will be able to state the risks and benefits of treatment for antenatal depression.
- Discuss the most updated literature on TMS and antenatal depression.
- Explain risks and benefits with pregnant patients with antenatal depression who are interested in TMS.
Format: On-Demand
Release Date: 12/10/2018
Expiration Date: 12/10/2020
Cost: Members: $25 | Non-members $50
Method of Physician Participation:
Learners will listen to each audio self-directed module while following along with the visual slides. Upon completion, each learner will answer evaluation questions to receive their CME Certificate.
Bibliographic Sources:
Included on speaker slides
Disclosure of Conflict of Interest:
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a postition to control the content of CME are listed below.
First Name |
Last Name |
Commercial Interest: Relationship |
Michelle |
Cochran |
Genomind: Speakers Bureau |
Kimberly |
Cress |
Speaker for Neuronetics & Medical Director of Houston NeuroCare Therapy |
Adrianne |
Davis |
Nothing to disclose |
Deborah |
Kim |
Nothing to disclose |
Sheryl |
Morgan |
Nothing to disclose |
Randy |
Pardell |
Nothing to disclose |
Speaker: Deborah Kim, M.D.
Dr. Deborah Kim is a Clinical Associate Professor of Psychiatry at the Perelman School of Medicine at the University of Pennsylvania. She is a perinatal psychiatrist who specializes in the treatment of pregnant and postpartum women. Her NIMH funded research has focused on the use of transcranial magnetic stimulation for depressed, pregnant women as well as the effects of maternal early life adversity on pregnancy and infant outcomes. She is currently in private practice and offers deep TMS to patients with treatment resistant depression. Dr. Kim has been studying TMS for antenatal depression since 2005. She recently published the results of a randomized controlled trial regarding the use of TMS for antenatal depression.
Update on Theta Burst TMS and TMS for OCD - New FDA Information
Learning objectives:
- To learn about the recently FDA cleared use of theta burst tms for depression;
- To review the FDA clearance of TMS for treatment of OCD;
- To learn about the OCD treatment protocol, including symptom induction
Format: On-demand
Release Date: October 10, 2018
Cost: Members: $25 | Non-members $50
Method of Physician Participation: Learners will listen to each audio self-directed module while following along with the visual slides. Upon completion, each learner will answer evaluation questions to receive their CME Certificate.
Bibliographic Sources: See slides for bibliographic sources for further study.
Disclosure of Conflict of Interest:
The following table of disclosure information is provided to learners and contains the relevant financial relationships that each individual in a position to control the content disclosed to Amedco. All of these relationships were treated as a conflict of interest and have been resolved. (C7 SCS 6.1-‐6.2, 6.5)
All individuals in a position to control the content of CE are listed in the program book. If their name is not listed below, they disclosed that they had no relevant financial relationships with commercial interests.
First Name |
Last Name |
Commercial Interest: Relationship |
Michelle |
Cochran |
Genomind: Speakers Bureau |
Kimberly |
Cress |
Speaker for Neuronetics & Medical Director of Houston NeuroCare Therapy |
Adrianne |
Davis |
Nothing to disclose |
Deborah |
Kim |
Nothing to disclose |
Sheryl |
Morgan |
Nothing to disclose |
Randy |
Pardell |
Nothing to disclose |
Speakers: Daniel Press, MD & David Feifel, MD, PhD
Dr. Press received his undergraduate degree from the University of Pennsylvania and his medical degree from the University of Connecticut School of Medicine. He trained in Neurology at the Harvard Longwood Neurology Training Program and did fellowship training in both Behavioral Neurology (1997-1999) and Movement Disorders (1999-2000). He is the Clinical Director fo the Cognitive Neurology Unit at BIDMC and is currently an Associate Professor in Neurology at Harvard Medical School. He is the Clinical Director of the Berenson Allen Center for Noninvasive Brain Stimulation at Beth Israel Deaconess Medical Center and is the co-chair of the Clinical Standards Committee of the Clinical TMS Society, where he is also a board member. He has over 40 publications in TMS and related fields, and does NIH funded clinical studies in TMS.
Dr. Feifel earned a Bachelor of Science, Master’s Degree and a Ph.D. (neurobiology) from the University of Toronto, Canada, where he also earned a Medical Degree. After completing an internship in Internal Medicine at the Toronto General Hospital, Dr. Feifel completed his residency training in Psychiatry at the University of California, San Diego, where he served as Chief Resident for the UCSD Outpatient Psychiatry Services in 1994. He currently holds the rank of full Professor in the Department of Psychiatry and Neuroscience Program. Dr. Feifel conducts translational research in mental illness and he has authored or co-authored numerous original scientific research papers, abstracts and book chapters on the topic of psychiatric illness and their treatments. His research has received funding grants from the National Association for Research in Schizophrenia and Depression (NARSAD), the Scottish Rite Organization, the Stanley Medical Research Institute and the National Institutes of Health. Dr. Feifel is Director of the Neuropsychiatry and Behavioral Medicine Program, and he is the founder and Director of the UCSD Adult ADHD Program, as well as the UCSD TMS program.
La Estimulación Magnética Transcraneal: Un enfoque de probada eficacia para el tratamiento de la depresión
Está invitado a unirse a la Clinical TMS Society para el webinar “La Estimulación Magnetica Transcraneal: Un enfoque de probada eficacia para el tratamiento de la depresión”. Este seminario web en línea analizará como se aplica la terapia TMS para tratar la depresión y los datos científicos en los que se basa su uso.
Objetivos de aprendizaje:
- Tratamientos actuales para la depresión y la necesidad de métodos de tratamiento alternativos.
- Cómo funciona TMS y como es el tratamiento
- Evidencia de la eficacia de la terapia TMS
- Cómo identificar posibles candidatos para la terapia TMS
Date: Martes, 25 de Septiembre de 2018
Formato: Seminario Web
Costo: Miembro: $20 | Sin miembresia: $40
Michael Kabar, M.D. (Moderator) - El Dr. Kabar es un médico Peruano-Americano formado como psiquiatra en la Universidad de Maryland y en el programa de residentado del Condado de San Mateo en Palo Alto, California, donde fue "Chief Resident". Está certificado por el American Board of Psychiatry and Neurology y ejerció en el área de San Francisco durante casi 20 años en la práctica privada, en la Universidad de California en Berkeley y en otras instituciones donde se desempeñó como director médico. Fue uno de los pioneros del modelo A.C.T (Assertive Community Treatment) en California. Luego de hacer investigación en Berkeley, fue entrenado en el uso clínico de TMS por el Dr. Marcolin en la Universidad de Sao Paulo. Regresó al Perú en el año 2010 para convertirse en el pionero en el campo de la Neuromodulación al fundar el Instituto de Neuroestimulación de Lima, donde ha tratado a más de 400 pacientes. El Dr. Kabar ha dado conferencias sobre TMS en la Asociación Latinoameicana de Psiquiatria (APAL) y otros congresos regionales e internacionales, incluyendo la Clinical TMS Society en Atlanta y en New York.
Matías Bonanni, M.D., M.Sc - El Dr. Bonanni es el Director del Instituto de Neurociencias Aplicadas a la Clínica (INAC) en Buenos Aires, donde es el Jefe del Departamento de Neuromodulación. Se graduó con honores en la Facultad de Medicina de la Universidad del Salvador en Argentina y completó su especialidad en Psiquiatría en el Hospital Neuropsiquiátrico J.T.Borda y en la Universidad de Buenos Aires. Es Magister en Psiconeurofarmacología y en Psiconeuroinmunoendocrinología de la Universidad Favaloro. Es Fellow Internacional de la Asociación de Psiquiatría Americana (APA) y Presidente del Capítulo de Tratamientos no Farmacológicos de la Asociación Argentina de Psiquiatría (AAP). Es profesor Titular de Bases Biológicas de la Conducta Humana en la Universidad de Belgrano. Inicia su entrenamiento en TMS en la Universidad de Harvard y en 2006 incorpora la técnica al INAC, siendo el primer centro de TMS en Argentina, desde entonces la ha aplicado tanto en un contexto clínico como en investigación en diferentes patologías. Paralelamente el Dr. Bonanni es miembro de diferentes asociaciones científicas nacionales e internacionales.
Transcranial Magnetic Stimulation: Physics, Devices, and Modeling
Learning objectives:
- Review the fundamental physical principles and constraints of TMS
- Overview existing and novel stimulators and coil designs
- Discuss electric field modeling of TMS
Date: On-demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Speaker: Zhi-De Deng, PhD
Dr. Zhi-De Deng is a Research Fellow at the National Institute of Mental Health Noninvasive Neuromodulation Unit, and Adjunct Assistant Professor in the Department of Psychiatry and Behavioral Sciences, Duke University School of Medicine. He received the S.B. degree in physics in 2006, S.B. and M.Eng. in electrical engineering and computer science in 2007, with a minor in economics, from the Massachusetts Institute of Technology. He received M.Phil. in 2011 and Ph.D. in electrical engineering in 2013, with a graduate minor in neuroscience, from Columbia University. He completed postdoctoral training in 2014 at Duke Psychiatry. His primary research focuses on the development of brain stimulation technology, electromagnetic field modeling and optimization of various neuromodulation modalities. His work on electric field modeling of transcranial magnetic stimulation coils was instrumental not only in understanding of the physics of TMS, but also provided helpful guidance for FDA clearance of various devices. He has received career development award from the National Center for Advancing Translational Sciences and NARSAD Young Investigator Award to develop the next generation seizure therapy. His vision is to transform psychiatry through engineering innovation.
Click the link to access the slides: http://www.zzzdeng.net/files/Deng_CTMSS_20180904.pdf
Peers & Magnets: A TMS Roundtable Discussion
Date: On-Demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Panelists: Richard Bermudes, MD, Philip Janicak, MD, and Karl Lanocha, MD
Dr. Bermudes, Dr. Lanocha, and Dr. Janicak each have over 20 years’ experience in the field of TMS therapy. They have authored or co-authored several peer-reviewed articles, guidelines, reviews and book chapters on TMS. Recently, Dr. Bermudes, Dr. Janicak, and Dr. Lanocha authored and co-edited “Transcranial Magnetic Stimulation: Clinical Applications for Psychiatric Practice”, a book with key research findings on TMS as well as its potential to be used for other conditions such as OCD, PTSD, Adolescent Depression and mild dementia.
July 18th, 2018 5:00 PM Pacific through 6:00 PM Pacific
Phone: 845-392-3238
Email: info@clinicaltmssociety.org
Grand Rounds Webinar | |
Clinical TMS Society Member | $ 25.00 |
Non-Member | $ 50.00 |
rTMS Treatment of Migraines: An Interrupted Time-Series Study Design
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: rTMS Treatment of Migraines: An Interrupted Time-Series Study Design by speaker Mahmoud (Max) Okasha, MD, MRCPsych, DPM, DLFAPA.
Learning objectives:
- Explain how CSD is the most likely mechanism of pathogenesis in Migraines
- Discuss the treatment of migraines with rTMS
- Utilize an interrupted-time series design as an alternative to double blind active versus sham treatment
Date: on-demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Speaker: Mahmoud (Max) Okasha, MD, MRCPsych, DPM, DLFAPA
Dr. Okasha is the Medical Director of Comprehensive Psychiatric Care, a private practice located in Norwich Connecticut where he is also the Primary Investigator (P.I.) and has conducted over 70 clinical trials. He is an Associate Clinical Professor at the Department of Psychiatry at Yale School of Medicine.
Brain Stimulation for PTSD: Review and Updates
Brain Stimulation for PTSD: Review and Updates
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Brain Stimulation for PTSD: Review and Updates by speaker William Sauvé, MD.
Learning objectives:
- Review current approaches to PTSD using brain stimulation modalities.
- Learn theories underlying different brain stimulation approaches for PTSD
- Review latest literature for brain stimulation currently under study for PTSD
Date: On-demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Speaker: William Sauvé, MD
William Sauvé, MD, is a Regional Medical Director for Greenbrook TMS NeuroHealth Centers, a dedicated center for the treatment of depression using Transcranial Magnetic Stimulation. After receiving his medical degree from the Uniformed Services University of the Health Sciences in Bethesda, Maryland, Dr Sauvé completed his residency in adult psychiatry in the National Capital Consortium in Washington, DC, which includes the National Naval Medical Center in Bethesda, Walter Reed Army Medical Center in Washington, DC, and Malcolm Grow Medical Center at Andrews Air Force Base in Maryland. Shortly afterward, he was deployed to the Al Anbar Province, Iraq, as the regimental psychiatrist for the 7th Marine Regiment. After 11 years of activeduty service, he left the US Navy to become Military Clinical Director at Poplar Springs Hospital. Dr Sauvé is certified by the American Board of Psychiatry and Neurology, Inc. Dr Sauvé recently coauthored “The Science of Transcranial Magnetic Stimulation” with Laurence Crowther for the July issue of Psychiatric Annals. He is a member of the American Psychiatric Association and a Faculty Member at the Neuroscience Education Institute.
Citation: Sauvé, W. M. and L. J. Crowther (2014). “The Science of Transcranial Magnetic Stimulation.” Psychiatric Annals 44(6): 279-283.
Deep TMS as a Treatment for Psychiatric Disorders
Learning objectives:
- Principles of Deep TMS
- Basis of its Use in Psychiatric Disorders
- Review of the Literature for the Use in Depression and Psychiatric Disorders
Date: On-demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Speaker: Oscar G. Morales, MD
Dr. Morales is the founder (2009) and medical director of the McLean Hospital TMS Service, the first in the Harvard Medical School and Partners Healthcare system dedicated to psychiatric treatments and investigation. He is responsible for all TMS activities including clinical, training, and current investigation of TMS in treating psychiatric disorders. Dr. Morales is on the faculty of the MGH/McLean Adult Psychiatry Residency Training Program and is involved in the training of Harvard students, residents, fellows, and psychiatrists. Dr. Oscar G. Morales, MD, is Senior Medical Advisor for Achieve TMS, the largest TMS provider in America. He was involved in the efforts that
led Massachusetts Medicare to approve TMS for depression and soon after with the largest private health insurance companies. Dr. Morales pioneered the development of TMS, as a Fellow, he participated in the investigation that led FDA to approve TMS for the treatment of depression (2008) and was the McLean site primary investigator for a worldwide trial that resulted in FDA approval of deep TMS for the treatment of depression (2013). He is an expert in the National Network of Depression Centers (NNDC) TMS Task Group, which develops guidelines, recommendations and collaborative research at a national level. Dr. Morales is Chair of the Brain Stimulation for Anxiety and Depression (BRASFAD) working group of the Depression and Anxiety Division (DAD) at McLean Hospital.
Peers & Magnets: A TMS Roundtable Discussion
Get your questions answered by your Society peers and leaders!
Topics Include:
- Practice development & compliance issues
- Ways to optimize clinical outcomes
- How to choose the right TMS system
- TMS training and supervision of staff
- TMS education
- Physician recruiting
- Marketing your TMS practice
- Other as determined by questions
Date: On-Demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Roundtable Discussion Panelists:
Paul E. Croarkin, DO, MS | Mayo Clinic College
Paul Croarkin, DO, MS is Associate Professor of Psychiatry, and the
Division Chair for Child and Adolescent Psychiatry for the Mayo Clinic
College of Medicine and Science. He is currently the Society’s Vice
President/President Elect and co-chair of the Research Committee. Dr.
Croarkin’s area of expertise is in Child and Adolescent Psychiatry and
Research on Off-Label Indications.
Todd Hutton, MD | Southern California TMS Center
Todd Hutton, MD is the Chief Medical Director for Southern California
TMS Center and the Associate Professor of Psychiatry for Keck School
of Medicine at USC. He is currently the Society’s Treasurer and
co-chair of the 2018 Annual Meeting Committee. Dr. Hutton has
experience with adult psychiatric conditions, multi-location clinical practice, and
staff hiring & training.
Kevin Kinback, MD | Advanced TMS Center
Kevin Kinback, MD is the Director at Advanced TMS Center, and Assistant
Professor of Psychiatry for the School of Medicine at Loma Linda
University. He currently serves on the Society’s Board of Directors and is
the co-chair of the Insurance Committee. Dr. Kinback’s area of expertise
is the business side of TMS, contracting, hiring associates, insurance
matters, risk management and safety protocols, handling complex
patients (i.e. VNS, h/o migraines, PD, etc), and tips to improve tolerance.
Creating an Effective Research Poster
Learning objectives:
- Learn the process of designing an informative, yet aesthetically pleasing research poster
- Understand how to translate your research onto a poster and make the biggest impact
Date: On-Demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Presenter: Valerie Metzger-Smith, B.S. - Research Manager
Ms. Metzger-Smith has been working with TMS in clinical research at the VA San Diego Healthcare System since 2014. She is an expert in TMS neuronavigation software and hardware operation as well as TMS treatment set-up and troubleshooting. In addition, she has successfully designed and presented 5 research posters over the past two years, each pertaining to the use of TMS as a treatment modality.
Conferences Presented At:
- Society for Neuroscience, San Diego 2016
- Clinical TMS Society, San Diego 2017
- Association of Military Surgeons of the United States, Washington D.C. 2017
Experience:
- Lead technician for TMS treatment sessions since 2014
- Processes anatomical MRI data in Brain voyager QX including cortex segmentation, inflation and manual repair of artifacts
- Completes real-time neuronavigation module setup and co-registration with TMS
Active Studies:
- Long Term Efficacy of rTMS in Managing MTBI-Related Headache
- Improving functions in Veterans with Post-traumatic Peripheral Neuropathic Pain
- Alleviating Headache and Pain in GWI with Neuronavigation Guided rTMS
Completed Studies:
- Effect of low frequency transcutaneous magnetic stimulation on sensory and motor transmission
- Leung A, Shukla S, Lee J, Metzger-Smith V, He Y, Chen J, Golshan S: Effect of low frequency transcutaneous magnetic stimulation on sensory and motor transmission. Bioelectromagnetics; 2015 (PMCID 25989482)
- Left Dorsolateral Prefrontal Cortex rTMS in Alleviating MTBI Related Headaches and Depressive Symptoms
- Leung, A., Metzger-Smith, V., He, Y., Cordero, J., Ehlert, B., Song, D., . . . Lee, R. (2017). Left Dorsolateral Prefrontal Cortex rTMS in Alleviating MTBI Related Headaches and Depressive Symptoms. Neuromodulation: Technology at the Neural Interface. doi:10.1111/ner.12615
Beyond One-Size-Fits-All: Tailoring the rTMS Protocol to the Patient
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Beyond One-Size-Fits-All: Tailoring the rTMS Protocol to the Patient by speaker Jonathan Downar, MD, PhD, FRCPC.
Learning objectives:
- To review recent advances in understanding the neural networks underlying dimensions of illness in depression
- To review clinical presentations assoiciated with these dimensions of illness
- To review recent advances in selecting the target of stimulation so as to address these specific dimensions of illness
Date: On-Demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Speaker: Jonathan Downar, MD, PhD, FRCPC
Dr Jonathan Downar is the director of the MRI-Guided rTMS clinic at the Toronto Western Hospital. The clinic uses non-invasive brain stimulation to treat medication-resistant depression and other psychiatric illnesses. With >600 referrals annually, it is among the highest volume brain stimulation clinics in North America.
Dr Downar also holds the position of Scientist at the Krembil Research Institute. As a translational clinician-scientist, his work focuses on developing new indications, better treatment techniques, and more cost-effective protocols for non-invasive brain stimulation in psychiatry. He has held peer-reviewed funding from CIHR, the NIH, Brain Canada, the Klarman Family Foundation, the Krembil Foundation, and the Buchan Family Foundation. His work has been published in leading journals including Trends in Cognitive Science, Biological Psychiatry, Neuropsychopharmacology, Brain Stimulation, JAMA Psychiatry, and Nature Neuroscience..
Clinical TMS Society Community Education Slide Deck
Join the Clinical TMS Society for the unveiling of the CTMSS Community Education Slide Deck. This Slide Deck is designed to raise awareness and teach the community and prospective patients about TMS therapy for the treatment of depression.
Learning objectives:
- Understand the need and importance of educating the public on TMS therapy
- Become familiar with the slides and content of the speaker notes
At the conclusion of this Grand Rounds webinar, the Community Education Slide Deck will be made available to Clinical TMS Society members for educational purposes by completing the Member User Agreement. See your confirmation email for details.
Date: On-demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25
* must be a current member to view this Grand Rounds Webinar
Presenter: Bob Sammons, M.D., Ph.D
Dr. Bob Sammons received a bachelor’s and master’s degree from
Auburn University, a Ph.D. in clinical psychology from the University of North Carolina at Greensboro, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in 1971. He has practiced adult psychiatry in Grand Junction for 29 years. He received training in TMS in 2006 from Dr. Alvaro Pascual-Leone and from Dr. Mark George in 2017. He is Medical Director for TMS Solutions with TMS offices in various locations in the West. He has been known to cook a little BBQ.
Advancing the Use of TMS in the Treatment of Neuropsychiatric Disorders
You’re invited to join the Clinical TMS Society for this installment of our Grand Rounds Webinar Series: Advancing the Use of TMS in the Treatment of Neuropsychiatric Disorders by speaker Paul Fitzgerald, Ph.D., MAPrc.
Learning objectives:
- To provide a background understanding of the use of different TMS paradigms applied in the treatment of depression
- To overview recent research exploring variations in TMS treatment dose
- To overview recent research evaluating accelerated forms of TMS treatment
Date: On-Demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members $50
Speaker: Paul Fitzgerald, PhD, MAPrc
Professor Paul Fitzgerald is Professor of Psychiatry at Epworth Healthcare, Monash University and deputy director of Monash Alfred Psychiatry Research Centre. He has been conducting research with transcranial magnetic stimulation and other brain stimulation treatments for 20 years including over 15 clinical trials in depression, schizophrenia, OCD and other disorders. He has published over 350 journal articles, been cited over 10,000 times and has held 3 consecutive NHMRC Practitioner Fellowships. He has trained over 300 clinicians in the application of TMS treatment and run the largest and busiest TMS program in Australia for over 10 years.
Clinical TMS Society Clinician Presentation Slide Deck
Learning objectives:
- Understand the goal of training clinicians on the CTMSS
Clinician Presentation Slide Deck - Become familiar with the slides and content of the Slide Deck
- Become aware of the Power Point speaker notes content and use
At the conclusion of this Grand Rounds webinar, members may gain access to the Slide Deck for educational purposes by completing the Member User Agreement. See Confirmation email for details.
Thank you for your interest in utilizing the Clinical TMS Society Clinician Presentation Slide Deck to promote further awareness and education of TMS.
Date: On-demand
Format: Webinar using Zoom Video Communications
Cost: Members: $25
* must be a current member to view this Grand Rounds Webinar
Presenter: Bob Sammons, M.D., Ph.D
Dr. Bob Sammons received a bachelor’s and master’s degree from
Auburn University, a Ph.D. in clinical psychology from the University of North Carolina at Greensboro, and a medical degree from the University of North Carolina at Chapel Hill. He did a residency in psychiatry at the University of Virginia as well as a forensic psychiatry fellowship. While a Captain in the Air Force he helped set up and run the treatment phase of the Air Force Drug Treatment program in 1971. He has practiced adult psychiatry in Grand Junction for 29 years. He received training in TMS in 2006 from Dr. Alvaro Pascual-Leone and from Dr. Mark George in 2017. He is Medical Director for TMS Solutions with TMS offices in various locations in the West. He has been known to cook a little BBQ.
Review the NNDC and APA Consensus Recommendations for the Clinical Application of rTMS in the treatment of Depression
You’re invited to join the Clinical TMS Society for the next installment of our Grand Rounds Webinar Series: Review the NNDC and APA Consensus Recommendations for the Clinical Application of rTMS in the treatment of Depression by speaker Shawn M. McClintock, PhD, MSCS.
Attendees will learn:
- Details of the FDA label for treating major depressive disorder in adults
- To identify the parameters for the safe and useful administration of rTMS
- To describe measurement-based care and the variables to assess before starting and during the rTMS course
Date: Tuesday, August 8, 2017
Time: 8:00pm (EST) / 5:00pm (PST)
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members: $50
Speaker: Shawn M. McClintock, PhD, MSCS
Dr. McClintock is an Associate Professor in the Department of Psychiatry at UT Southwestern Medical Center and is Adjunct Associate Professor in the Department of Psychiatry and Behavioral Sciences at the Duke University School of Medicine. He received his Ph.D. in Clinical Psychology from UT Southwestern Medical Center (2006). In 2008, Dr. McClintock was appointed a NIH Clinical Scholar in the UT Southwestern Medical Center Department of Clinical Sciences where he received his M.S. in Clinical Sciences with Distinction (2011). He completed a National Institute of Mental Health T-32 Postdoctoral Fellowship in mood disorder research at UT Southwestern Medical Center and a postdoctoral fellowship in brain stimulation and neurotherapeutic modulation at Columbia University College of Physicians and Surgeons and the New York State Psychiatric Institute.
Dr. McClintock is a globally recognized expert on the use of translational neurocognitive methods to develop new and safe neuromodulation interventions for the treatment of major depressive disorder. Such interventions include Electroconvulsive therapy (ECT), magnetic seizure therapy (MST), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), and transcranial direct current stimulation (tDCS). Also, he is developing newer translational methods of neurocognitive assessment in order to elucidate similar and divergent cognitive processes across species, with the goal of identifying underlying cognitive component processes of neurocognitive sequelae in patients treated with neuromodulation interventions.
Cranial Nerve Stimulation: Old and New Neuromodulation Therapies for CNS Disorders
Attendees will be able to:
- To describe the relationship between cranial nerve circuitry and higher cortical and subcortical structures involved in neuropsychiatric disorders
- To evaluate the preclinical, translational, and clinical trials data on new cranial nerve stimulation modalities such as trigeminal nerve stimulation (TNS)
- To consider the evidence base of TNS in epilepsy,depression, PTSD, ADHD, and migraine, and regulatory approvals in the EU, Canada, Australia, and the U.S.
Date: Tuesday, June 6 2017
Time: 8:00pm (EST) / 5:00pm (PST)
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members: $50
Speaker: Ian A. Cook, MD
Ian A. Cook, MD, is a Professor of Psychiatry and Biobehavioral Sciences and of Bioengineering at UCLA, where he founded the TMS program in 2009. He is the Director of the UCLA Depression Research & Clinic program and was the first to hold the Miller Family Endowed Chair in Depression Research. He has lead translational research projects for over 20 years at UCLA, initially focusing on neurophysiological and neuroimaging biomarkers related to treatment for depression and dementia, and more recently on treatment development using neuromodulation approaches. He has been PI on research grants examining vagus nerve stimulation, transcranial magnetic stimulation, and trigeminal nerve stimulation. He was the first physician to use trigeminal nerve stimulation as a psychiatric treatment, initially in major depression and then in PTSD, and is an inventor on over 25 issued and provisional U.S. patents for neuromodulation devices and methods. He has published over 120 original research reports, along with dozens of review articles, book chapters, and invited editorial sand commentaries.
Dr. Cook graduated from Princeton University with a B.S.E. in Electrical Engineering and Computer Science and Bioengineering, where his thesis examined the effects of electromagnetic fields on biological tissues. He graduated from the Yale School of Medicine before coming to UCLA for his psychiatry residency and NIMH research fellowship. He was elected Chair of the Faculty of the UCLA School of Medicine and simultaneously served as Chief of Staff of the Resnick Neuropsychiatric Hospital at UCLA. A Distinguished Fellow of the APA, he served on its Steering Committee on Practice Guidelines for 14 years, and led its electronic dissemination of evidence-based guidelines while serving on its Executive Committee. In 2011, he was tapped by Thomas Insel MD, then Director of the NIMH, to serve as a standing member of the Interventions Committee for Adult Disorders (ITVA) review group. Dr. Cook was elected to the Board of Directors of the Clinical TMS Society in 2013, the year it was founded.
Peers & Magnets: A TMS Roundtable Discussion
- Practice development & compliance Issues with TMS
- Ways to optimize clinical outcomes for patients with TRD (Treatment resistant depression)
- How to choose the right TMS system?
- TMS training and supervision of staff
- TMS education
- Physician recruiting
- Marketing your TMS Practice
Submit Your Questions:
The Peers & Magents Roundtable series is designed to allow attendees to submit questions prior to the webinar. If you have a question or topic that you would like the panelists to cover, CLICK HERE or email info@clinicaltmssociety.org. Please submit your question by Thursday, March 30th.
Date: Tuesday, April 4, 2017
Time: 8:00pm (EST) / 5:00pm (PST)
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members: $50
Panelist: Richard A. Bermudes
Dr. Bermudes is Board Certified in Adult Psychiatry and Family Medicine, with 20 years’ experience caring for patients. He founded TMS Health Solutions in 2007, serves as the practice’s Medical Director, and is an expert on TMS practice organization and policy development.
Originally from Sonoma County, Dr. Bermudes earned his medical degree from the University of California, San Diego in 1997. He served as Chief Resident for the Family Medicine/Psychiatry Combined Program at the University of Cincinnati, then completed a fellowship in cognitive therapy and cognitive therapy supervision at the Beck Institute for Cognitive Therapy and Research in Philadelphia, Pennsylvania.
Dr. Bermudes is a founding member of the Clinical TMS Society. He chaired the group first annual meeting in 2013 and was elected as its president in 2015. When he’s not at the office, Dr. Bermudes recharges by trail running and mountain biking, and is an ardent devotee of pourover coffee.
Panelist: Michelle R.M. Cochran, MD, FAPA
Michelle R. M. Cochran MD, FAPA currently works in a private practice in Nashville. She has experience treating a variety of psychiatric conditions, using therapy, counseling, medicines, neuro-modulation, and holistic options.
Dr. Cochran completed her medical training at the University of Louisville School of Medicine. She received postgraduate medical education at Vanderbilt University Medical Center where she completed a residency in Psychiatry.
A Diplomat of the American Board of Psychiatry and Neurology, Dr. Cochran is also a fellow of the American Psychiatric Association. Since 2011, Dr. Cochran has offered Transcranial Magnetic Stimulation to her patients as an option for the treatment of Major Depressive Disorder. Dr. Cochran and her staff have trained extensively in the use of repetitive Transcranial Magnetic Stimulation (rTMS) including training at Harvard, Duke and other specific advanced device trainings.
Dr Cochran speaks nationally on the use of rTMS in a clinical setting and is a active member of The Clinical TMS Society. Dr. Cochran has served on the annual committee for four years and was a co-chair of the annual meeting in Toronto, Canada. Presently she is on the executive board for the society as the current Vice President, and is the chair and coordinator for the Inagural Pulses conference to be held the day prior to this year's Clinical TMS Annual meeting.
Panelist: David Feifel MD
Dr. David Feifel is a Professor of Psychiatry at the University of California, San Diego where he is the founding Director of UCSD’s TMS program and the UCSD Center for Advanced Treatment of Mood and Anxiety Disorders. He is a board member of the Clinical TMS Society and also co-chairs its clinical standards committee
What's New With TMS for Depression:
This Grand Rounds webinar will:
- Discuss the latest TMS studies and research findings
- Provide a better understanding of when you can deviate from FDA approved TMS treatment doses
- Review evidence which supports potential deviations from FDA approved doses
Date: Tuesday, February 7, 2017
Time: 8:00pm (EST) / 5:00pm (PST)
Format: Webinar using Zoom Video Communications
Cost: Members: $25 | Non-members: $50
Speaker: Mark S. George, MD
As an undergraduate student in philosophy at Davidson College in Davidson, NC, Dr. George first began studying the relationship between mind and brain, or brain/behavior relationships. He has continued this interest throughout his career with a focus on using brain imaging and brain stimulation to understand depression and devise new treatments.
He received his medical degree from the Medical University of South Carolina in Charleston in 1985, where he continued with dual residencies in both neurology and psychiatry. He is board certified in both areas. Following his residency training he worked for one year (1990-91) as a Visiting Research Fellow in the Raymond Way Neuropsychiatry Research Group at the Institute of Neurology, Queen Square, London, England. He then moved to Washington, DC, working with Dr. Robert Post in the Biological Psychiatry Branch of the Intramural National Institute of Mental Health (NIMH). During his 4 years at NIMH he was one of the first to use functional imaging (particularly oxygen PET) and discovered that specific brain regions change activity during normal emotions. He then started using imaging to understand brain changes that occur in depression and mania, a quest that he and many others are still pursuing. This imaging work directly led to his pioneering use of a non-invasive brain stimulation method, transcranial magnetic stimulation (TMS), as a probe of neuronal circuits regulating mood, and to clinical trials using TMS as an antidepressant. In 1993 while at the NIMH, he discovered that daily prefrontal rTMS over several weeks could treat depression and ever since he has worked to grow the science of TMS, both in terms of how it works in the brain, and in critically evaluating its therapeutic applications, especially in the area of treating depression. In June 1998 at MUSC, he also helped pioneer another new treatment for resistant depression, vagus nerve stimulation (VNS). This was FDA approved in 2006. He and his group have used MRI imaging to understand VNS brain effects.
He is a world expert in brain stimulation, and depression, and is the editor-in-chief of a new journal he launched with Elsevier in 2008 called, Brain Stimulation: Basic, Translation and Clinical Research in Neuromodulation. He has been continuously funded by NIH and other funding agencies since his fellowships. He has received both a NARSAD Young Investigator and Independent Investigator Award to pursue TMS research in depression. He has received numerous international awards including the NARSAD Klerman Award (2000), NARSAD Falcone Award (2008) and the Lifetime Achievement Award (2007) given by the World Federation of Societies of Biological Psychiatry (WFSBP). In 2009 US News and World Report named him one of 14 ‘medical pioneers who are not holding back’. He is on several editorial review boards and NIH study sections, has published over 400 scientific articles or book chapters, and has written or edited 6 books.